Navigation Links
ERT Reports Fourth Quarter and Full Year 2008 Results

Q4 2008 Net Revenues - $30.1 million vs. $28.9 million in Q4 2007 - a 4.0% increase

Q4 2008 Diluted Net Income per Share - $0.11 vs. $0.10 in Q4 2007 - a 10.0% increase

Q4 2008 New Bookings of $45.1 million vs. $39.2 million in Q4 2007 - a 15.1% increase

2008 Net Revenues -- $133.1 million vs. $98.7 million in 2007 - a 34.9% increase

2008 Diluted Net Income per Share of $0.48 vs. $0.29 in 2007 - a 65.5% increase

2008 New Bookings of $187.2 million vs. $138.6 million in 2007 - a 35.1% increase.

PHILADELPHIA, Feb. 26 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (ERT) (Nasdaq: ERES), a leading provider of centralized ECG, eClinical technology, ePRO and other services to the pharmaceutical, biotechnology, medical device, and related industries, announced today results for the fourth quarter of 2008 and the twelve-month period ended December 31, 2008. Unless otherwise noted, all growth numbers refer to changes from the same period a year ago.

Highlights of the fourth quarter and the year were:

  • Net revenues were $30.1 million for the fourth quarter of 2008, a 4.0% increase from the fourth quarter of 2007. Net revenues for the full year 2008 were a record $133.1 million, up 34.9% from 2007.
  • Covance Cardiac Safety Services (CCSS) revenues, all of which related to acquired backlog, were $1.9 million in the fourth quarter of 2008 compared to $1.5 million in the prior year's quarter and were $10.1 million for the full year 2008 compared to $1.5 million in the prior year.
  • Gross margin percentage in the fourth quarter increased to 57.3% from 52.6% in the prior year's quarter. The gross margin percentage for the full year was 55.8%, up from 50.7% in 2007.
  • Operating income margin percentage in the fourth quarter was 28.6%, up from 26.1% in the prior year's quarter. Operating income margin for the full year was 28.8%, up from 22.5% in 2007.
  • The company's tax rate was 39.7% in the fourth quarter, compared to 35.9% in the prior year's quarter. The tax rate was 37.7% for the full year 2008 compared to 37.6% in 2007.
  • Net income was $5.7 million for the fourth quarter of 2008, a 9.8% increase from $5.2 million in the fourth quarter of 2007. Net income was $25.0 million for 2008, a 63.9% increase from $15.3 million in 2007.
  • Diluted net income per share was $0.11 in the fourth quarter of 2008 compared to $0.10 in the fourth quarter of 2007. For the full year 2008, diluted net income per share was $0.48, up from $0.29 in 2007.
  • New bookings in the fourth quarter were $45.1 million, an increase of 15.1% over the bookings in the prior year's fourth quarter and up sequentially from the $43.0 million in the third quarter of 2008. For 2008, new bookings were a record $187.2 million, up 35.1% from $138.6 million in 2007.
  • The percent of new bookings in Phase III/IV rose to 59.4%, up from 44.4% in the prior year's fourth quarter.
  • Backlog increased to $166.5 million as of December 31, 2008, an increase of 18.8% from the prior year. The annualized cancellation rate in the fourth quarter was 19.3% compared to 19.6% in the quarter ended September 30, 2008 and 15.3% in the prior year's fourth quarter.

Cash flow from operations for 2008 was $39.9 million, compared to $36.0 million in 2007. ERT ended the year with $66.4 million in cash, cash equivalents, and investments, up from $46.9 million at the end of 2007. The Company bought 439,749 shares of stock under its approved stock repurchase program in the fourth quarter at a total cost of $2.6 million.

"This quarter we began to feel the impact of the cautious and delayed decision-making that has marked our economy in general, and our industry in particular, in the past few months. This was most evident in our Thorough QT business, which accounted for the majority of the quarter's sequential revenue decline from the $33.9 million we reported in our September 2008 quarter," commented Dr. Michael McKelvey, President and CEO of ERT. "Despite this, we were very pleased that we could increase our gross margin to 57.3%. We were also pleased with the $45.1 million in new bookings and our gross book-to-bill ratio of 1.5, both up from the third quarter. As a whole, 2008 was very strong. We recorded record revenues, bookings and backlog. Our 2008 operating income margin of 28.8% was 630 basis points higher than our operating income margin for 2007, despite the costs that we incurred in the transfer of the acquired CCSS operations to our facility in Philadelphia. We grew net revenues by 34.9%, operating income by 72.6% (on top of the 86.0% increase in 2007), and backlog by 18.8%."

"In 2009 we anticipate lower revenues due mostly to delays in Thorough QT bookings and trial starts and also as a result of a higher proportion of our bookings being in longer-to-recognize Phase III studies," continued Dr. McKelvey. "Although the timing of when Thorough QT trials are performed is within the discretion of the sponsor, regulatory guidance ultimately requires that they be performed. Despite the challenges of the anticipated reduced revenues, our priorities are straightforward. First, we see opportunities to increase market share by continuing to win new and expanded exclusive or near-exclusive long-term enterprise contracts with large clients - including some with which we had very little business in the past. Second, we will focus on increasing the industry penetration of centralized ECGs by focusing on how centralization of ECGs can reduce our clients' costs as we believe the benefits of centralization of higher quality and more timely access are apparent. Third, we plan to continue to position ERT for the future by expanding our sales and marketing organization and our internal systems infrastructure. We believe that in difficult economic and financial times innovative market leaders can prosper and position themselves for increased growth in the future. Our strong, debt-free balance sheet, market leading position, enhanced reputation for project management quality and continued thought leadership in our industry position us well to take advantage of the current regulatory and development climate that seeks to enhance safety determination for new drugs."

2009 Guidance

The Company issued guidance for the first quarter and full year of 2009. This guidance reflects the anticipated delays in starts and awards of new Thorough QT studies, the cautious spending decisions of many of our clients, and a slight return to growth of the economy in the second half of 2009. ERT anticipates net revenues of between $21.0 million and $24.0 million and net income per diluted share of $0.01 to $0.04 for the quarter ending March 31, 2009. For the full year ending December 31, 2009, ERT anticipates net revenues of between $105 million and $125 million with earnings per diluted share of between $0.25 and $0.43.

Conference Call

Dr. McKelvey and Keith Schneck, the Company's Chief Financial Officer, will hold a conference call to discuss these results. The conference call will take place at 5:00 PM EST on February 26, 2009. For the conference call, interested participants should dial 1-866-730-5766 when calling within the United States or 1-857-350-1590 when calling internationally. Please use pass code 56911587. There will be a playback available as well. To listen to the playback, please call 1-888-286-8010 when calling within the United States or 1-617-801-6888 when calling internationally. Please use pass code 39831591 for the replay.

This call is being webcast by Thomson Financial and can be accessed at ERT's web site at The webcast may also be accessed at Thomson's Institutional Investor website at The webcast can be accessed for up to one year on either site.

About eResearchTechnology, Inc.

Based in Philadelphia, PA, eResearchTechnology, Inc. ( is a provider of technology and services to the pharmaceutical, biotechnology and medical device industries on a global basis. The Company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. The Company is also a leader in providing technology and services to streamline the clinical trials process by enabling its customers to automate the collection, analysis, and distribution of clinical data in all phases of clinical development.

This release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect our current views as to future events and financial performance with respect to our operations. These statements can be identified by the fact that they do not relate strictly to historical or current facts. They use words such as "aim," "anticipate," "are confident," "estimate," "expect," "will be," "will continue," "will likely result," "project," "intend," "plan," "believe," "look to" and other words and terms of similar meaning in conjunction with a discussion of future operating or financial performance. Specifically, statements include, but are not limited to, our 2009 financial guidance.

These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements. Factors that might cause such a difference include: unfavorable economic conditions; our ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects and internal issues at the sponsoring client; integration of acquisitions; competitive factors; technological development; and market demand. There is no guarantee that the amounts in our backlog will ever convert to revenue. Should the current economic conditions continue or deteriorate further, the cancellation rates that we have historically experienced could increase. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. Guidance is based on management's good faith expectations given current market conditions but that continued or further deterioration of general economic conditions, in addition to other factors cited elsewhere, could result in the company not achieving the revenue and earnings per diluted share guidance provided.

Forward-looking statements speak only as of the date made. We undertake no obligation to update any forward-looking statements, including prior forward-looking statements, to reflect the events or circumstances arising after the date as of which they were made. As a result of these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements included in this release or that may be made in our filings with the Securities and Exchange Commission or elsewhere from time to time by, or on behalf of, us.

                      eResearchTechnology, Inc. and Subsidiaries
                        Consolidated Statements of Operations
                       (in thousands, except per share amounts)

                                   Three Months Ended      Year Ended
                                       December 31,       December 31,
                                   2007        2008     2007      2008
                               (unaudited) (unaudited)       (unaudited)
    Net revenues:
        Licenses                   $687        $817   $2,700      $3,203
        Services                 21,565      21,748   69,547      99,258
        Site support              6,657       7,500   26,451      30,679

    Total net revenues               29          30       99         133

    Costs of revenues:
        Cost of licenses            105         206      304         755
        Cost of services          8,932       8,749   30,522      39,697
        Cost of site support      4,665       3,880   17,808      18,445

    Total costs of revenues          14          13       49          59

    Gross margin                     15          17       50          74

    Operating expenses:
        Selling and marketing     3,143       3,014   11,222      13,273
        General and
         administrative           3,343       4,453   12,258      18,181
        Research and
         development              1,178       1,171    4,333       4,394

    Total operating expenses          8           9       28          36

    Operating income                  8           9       22          38
    Other income, net               503         808    2,206       1,730

    Income before income taxes      8           9       24          40
    Income tax provision          2,887       3,734    9,205      15,123

    Net income                       $5          $6      $15         $25

    Basic net income per share    $0.10       $0.11    $0.30       $0.49

    Diluted net income per share  $0.10       $0.11    $0.29       $0.48

    Shares used to calculate
     basic net income per share  50,618      51,251   50,476      50,870

    Shares used to calculate
     diluted net income per
     share                       51,929      51,804   51,743      52,015

                       eResearchTechnology, Inc. and Subsidiaries
                               Consolidated Balance Sheets
                   (in thousands, except share and per share amounts)

                                          December 31, 2007 December 31, 2008
    ASSETS                                                    (unaudited)

    Current assets:
         Cash and cash equivalents               $38,082          $66,376
         Short-term investments                    8,797               50
         Accounts receivable, net                 26,718           29,177
         Prepaid income taxes                        743            1,892
         Prepaid expenses and other                3,087            2,885
         Deferred income taxes                       901            1,831
             Total current assets                 78,328          102,211

    Property and equipment, net                   33,347           29,639
    Goodwill                                      30,908           34,603
    Intangible assets                              3,849            2,149
    Deferred income taxes                          1,011                -
    Other assets                                     253              520

                Total assets                    $147,696         $169,122


    Current liabilities:
         Accounts payable                         $3,505           $3,971
         Accrued expenses                         11,875            8,140
         Income taxes payable                      2,352            2,492
         Current portion of capital lease
          obligations                              1,097               43
         Deferred revenues                        13,905           12,276
             Total current liabilities            32,734           26,922

    Capital lease obligations, excluding
     current portion                                  48                -
    Deferred rent                                    228            2,183
    Deferred income taxes                              -            1,332
    Other liabilities                              1,174            1,257

                Total liabilities                 34,184           31,694

    Stockholders' equity:
         Preferred stock-$10.00 par value,
          500,000 shares authorized,
          none issued and outstanding                  -                -
         Common stock-$.01 par value,
          175,000,000 shares authorized,
          58,870,291 and 59,950,257 shares
          issued, respectively                       589              600
         Additional paid-in capital               87,957           93,828
         Accumulated other comprehensive
          income                                   1,679           (2,716)
         Retained earnings                        85,477          110,479
         Treasury stock, 8,247,119 and
          8,686,868 shares at cost,
          respectively                           (62,190)         (64,763)

             Total stockholders' equity          113,512          137,428

                Total liabilities and
                 stockholders' equity           $147,696         $169,122

                     eResearchTechnology, Inc. and Subsidiaries
                       Consolidated Statements of Cash Flows
                                   (in thousands)

                                                      Year Ended December 31,
                                                         2007        2008

    Operating activities:
     Net income                                        $15,252      $25,002
     Adjustments to reconcile net income to net cash
        provided by operating activities:
       Depreciation and amortization                    15,129       16,038
       Cost of sales of equipment                        1,143          743
       Provision for uncollectible accounts                 30          189
       Share-based compensation                          2,004        2,604
       Deferred income taxes                              (521)       1,098
       Changes in operating assets and liabilities
          excluding CCSS acquisition:
        Accounts receivable                             (4,192)      (3,840)
        Prepaid expenses and other                         352           41
        Accounts payable                                (2,147)         175
        Accrued expenses                                 2,928          (80)
        Income taxes                                     3,658       (1,290)
        Deferred revenues                                2,487         (667)
        Deferred rent                                     (122)         (64)
         Net cash provided by operating activities      36,001       39,949

    Investing activities:
     Purchases of property and equipment               (11,073)     (10,969)
     Purchases of investments                          (58,008)           -
     Proceeds from sales of investments                 91,555        8,747
     Payments for acquisition                          (35,800)      (6,042)
         Net cash used in investing activities         (13,326)      (8,264)

    Financing activities:
     Repayment of capital lease obligations             (2,504)      (1,102)
     Proceeds from exercise of stock options             1,655        2,369
     Stock option income tax benefit                       760          849
     Repurchase of common stock for treasury                 -       (2,573)
         Net cash used in financing activities             (89)        (457)

    Effect of exchange rate changes on cash                 (1)      (2,934)

    Net increase in cash and cash equivalents           22,585       28,294
    Cash and cash equivalents, beginning of period      15,497       38,082

    Cash and cash equivalents, end of period           $38,082      $66,376 

SOURCE eResearchTechnology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. QMed, Inc. Reports July Medicare SNP Enrollments
3. Phlo Affiliate Reports Expanded Coverage to Oregon Border
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
6. Carrington Reports Second Quarter 2007 Results
7. Avitar Reports Third Quarter Financial Results for Fiscal 2007
8. Response Genetics Reports Second Quarter 2007 Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Transgenomic, Inc. Reports Second Quarter 2007 Results
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
(Date:11/24/2015)... India , November 24, 2015 ... a new market research report "Oligonucleotide Synthesis Market by ... Application (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, ... 2020", published by MarketsandMarkets, the market is expected to ... Million in 2015, at a CAGR of 10.1% during ...
(Date:11/24/2015)... IN (PRWEB) , ... November 24, 2015 , ... The ... newest Special Interest Group (SIG), MultiGP, also known as Multirotor Grand Prix, to represent ... the last few years. Many AMA members have embraced this type of racing and ...
(Date:11/24/2015)... 24, 2015 --> ... report released by Transparency Market Research, the global non-invasive ... CAGR of 17.5% during the period between 2014 and ... Global Industry Analysis, Size, Volume, Share, Growth, Trends and ... testing market to reach a valuation of US$2.38 bn ...
(Date:11/24/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: ... 11,000 post-share consolidation (or 1,100,000 pre-share consolidation) Series ... Warrants") subject to the previously disclosed November 1, ... which will result in the issuance of 365,518 ... issuance of such shares, there will be approximately ...
Breaking Biology Technology:
(Date:10/29/2015)... Daon, a global leader in mobile biometric ... new version of its IdentityX Platform , IdentityX ... have already installed IdentityX v4.0 and are ... FIDO UAF certified server component as an option ... features. These customers include some of the largest and ...
(Date:10/27/2015)... -- In the present market scenario, security is one ... verticals such as banking, healthcare, defense, electronic gadgets, and ... secure & simplified access control and growing rate of ... bank accounts, misuse of users, , and so on. ... and smartphones are expected to provide potential opportunities for ...
(Date:10/26/2015)... -- Delta ID Inc., a company focused on bringing secure ... announced its ActiveIRIS® technology powers the iris recognition feature ... NTT DOCOMO, INC in Japan . ... include iris recognition technology, after a very successful introduction ... 2015, world,s first smartphone to have this capability. ...
Breaking Biology News(10 mins):